Skip to content

Study · Randomized controlled trial · 2017

3 results

Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors.

Cosman F, Hattersley G, Hu MY, Williams GC, Fitzpatrick LA, Black DM

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research28 Sept 2016Cited by 63 (Europe PMC)

PMID27612281 (opens in a new tab)DOI10.1002/jbmr.2991 (opens in a new tab)PepBankPUB-27612281
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, baseline risk factors showed no clinically meaningful interaction with abaloparatide effects on vertebral fractures.

    In plain wordsIn women with osteoporosis, baseline risk factors did not meaningfully change abaloparatide effects on vertebral fractures versus placebo.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeBaseline-risk interaction with vertebral fracture effect
    Study

    n: not reported in source

    Comparator
    placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Forest plots show that there were no clinically meaningful interactions between any of the baseline risk factors and the treatment effect of abaloparatide-SC on new morphometric vertebral fractures, nonvertebral fractures, or BMD increases.
    1 context sentence
    Summary · context
    The analysis reported here was designed to evaluate whether fracture risk reductions and BMD accrual were consistent across different levels of baseline risk.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, baseline risk factors showed no clinically meaningful interaction with abaloparatide effects on nonvertebral fractures.

    In plain wordsIn women with osteoporosis, baseline risk factors did not meaningfully change abaloparatide effects on nonvertebral fractures versus placebo.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeBaseline-risk interaction with nonvertebral fracture effect
    Study

    n: not reported in source

    Comparator
    placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Forest plots show that there were no clinically meaningful interactions between any of the baseline risk factors and the treatment effect of abaloparatide-SC on new morphometric vertebral fractures, nonvertebral fractures, or BMD increases.
    1 context sentence
    Summary · context
    The analysis reported here was designed to evaluate whether fracture risk reductions and BMD accrual were consistent across different levels of baseline risk.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, baseline risk factors showed no clinically meaningful interaction with abaloparatide effects on BMD increases.

    In plain wordsIn women with osteoporosis, baseline risk factors did not meaningfully change abaloparatide effects on bone density versus placebo.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeBaseline-risk interaction with BMD effect
    Study

    n: not reported in source

    Comparator
    placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Forest plots show that there were no clinically meaningful interactions between any of the baseline risk factors and the treatment effect of abaloparatide-SC on new morphometric vertebral fractures, nonvertebral fractures, or BMD increases.
    1 context sentence
    Summary · context
    The analysis reported here was designed to evaluate whether fracture risk reductions and BMD accrual were consistent across different levels of baseline risk.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01343004

Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women

Radius Health, Inc.n = 2,463Apr 2011 to Oct 2014

Osteoporosis · Postmenopausal Osteoporosis

Trial pageClinicalTrials.govUpdated 1 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.